{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06312020",
            "orgStudyIdInfo": {
                "id": "HZNP-HZN-1116-201"
            },
            "organization": {
                "fullName": "Amgen",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome",
            "officialTitle": "A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sj\u00f6gren's Syndrome",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "a-phase-study-to-investigate-efficacy-and-safety-of-hzn-in-participants-with-sjogren-s-syndrome"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-26",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-16",
            "studyFirstSubmitQcDate": "2024-03-07",
            "studyFirstPostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Amgen",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).",
            "detailedDescription": "The study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity; Population 2 will include participants with moderate to severe subjective symptoms. This study will include 3 periods: screening (5 weeks), treatment period (48 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized to receive subcutaneous (SC) dose of HZN-1116 or placebo.\n\nAcquired from Horizon in 2024."
        },
        "conditionsModule": {
            "conditions": [
                "Sjogren's Syndrome"
            ],
            "keywords": [
                "SS",
                "Sjogren's",
                "HZN-1116",
                "Autoimmune disease",
                "Dry Eye syndrome",
                "VIB1116"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 262,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HZN-1116 Dose 1 in Population 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Dose 1 of HZN-1116",
                    "interventionNames": [
                        "Drug: HZN-1116"
                    ]
                },
                {
                    "label": "HZN-1116 Dose 2 in Population 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Dose 2 of HZN-1116",
                    "interventionNames": [
                        "Drug: HZN-1116"
                    ]
                },
                {
                    "label": "Placebo in Population 1",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive Placebo matched to HZN-1116",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "HZN-1116 Dose 1 in Population 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Dose 1 of HZN-1116",
                    "interventionNames": [
                        "Drug: HZN-1116"
                    ]
                },
                {
                    "label": "HZN-1116 Dose 2 in Population 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Dose 2 of HZN-1116",
                    "interventionNames": [
                        "Drug: HZN-1116"
                    ]
                },
                {
                    "label": "HZN-1116 Dose 3 in Population 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Dose 3 of HZN-1116",
                    "interventionNames": [
                        "Drug: HZN-1116"
                    ]
                },
                {
                    "label": "HZN-1116 Dose 4 in Population 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Dose 4 of HZN-1116",
                    "interventionNames": [
                        "Drug: HZN-1116"
                    ]
                },
                {
                    "label": "Placebo in Population 2",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive Placebo matched to HZN-1116",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "HZN-1116",
                    "description": "Subcutaneous Administration",
                    "armGroupLabels": [
                        "HZN-1116 Dose 1 in Population 1",
                        "HZN-1116 Dose 1 in Population 2",
                        "HZN-1116 Dose 2 in Population 1",
                        "HZN-1116 Dose 2 in Population 2",
                        "HZN-1116 Dose 3 in Population 2",
                        "HZN-1116 Dose 4 in Population 2"
                    ],
                    "otherNames": [
                        "VIB1116"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Subcutaneous Administration",
                    "armGroupLabels": [
                        "Placebo in Population 1",
                        "Placebo in Population 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from baseline in European Alliance of Associations for Rheumatology (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) (Population #1)",
                    "timeFrame": "At Week 48"
                },
                {
                    "measure": "Change from baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) (Population #2)",
                    "timeFrame": "At Week 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline in ESSDAI (Population #1)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Proportion of Participants achieving ESSDAI [5] response (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in ESSPRI pain domain score (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in Diary for Assessing Sjogren's Patient-Reported Outcome Index (DASPRI) pain domain score (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in ESSPRI fatigue domain score (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in DASPRI fatigue domain score (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in ESSPRI dryness domain score (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in DASSPRI dryness domain score (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in tender joint count (TJC) (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in swollen joint count (SJC) (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in 36-item Short Form Survey (SF-36) physical component score (PCS) (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in 36-item Short Form Survey (SF-36) mental component score (MCS) (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in patient-reported outcomes measurement information system (PROMIS)-Fatigue SF-10a (Population #1)",
                    "timeFrame": "At Week 24 and Week 48"
                },
                {
                    "measure": "Change from baseline in DASPRI (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Proportion of Participants achieving ESSPRI [1.5] response (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Change from baseline in ESSPRI pain domain (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Change from baseline in ESSPRI fatigue domain (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Change from baseline in ESSPRI dryness domain (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Change from baseline in SF-36 PCS Score (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Change from baseline in 36-item Short Form Survey (SF-36) mental component score MCS (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Change from baseline in PROMIS-Fatigue SF-10a (Population #2)",
                    "timeFrame": "At Week 24"
                },
                {
                    "measure": "Serum concentration of HZN-1116 starting at Week 1 through study completion (Population #1 and #2)",
                    "timeFrame": "Up to Week 60"
                },
                {
                    "measure": "Proportion of Participants who develop anti drug antibodies (ADA) over time (Population #1 and #2)",
                    "timeFrame": "Up to Week 60"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.\n* Have an ESSDAI score of \\>= 5 at screening (only for Population 1).\n* Have an ESSPRI score of \\>= 5 at screening (only for Population 2).\n* Have an ESSDAI score of \\< 5 at screening (only for Population 2).\n* Positive for anti-Ro autoantibodies, rheumatoid factor (RF) at screening, or both at screening.\n\nKey Exclusion Criteria:\n\n* Concomitant system sclerosis.\n* Active malignancy or history of malignancy within the last 5 years with exception of in situ carcinoma of the cervix treated with apparent success with curative therapy \\> 12 months prior to screening; OR cutaneous basal cell carcinoma following presumed curative therapy.\n* Individuals who are pregnant or lactating or planning to become pregnant during the study.\n* Individuals who have a positive test for, or have been treated for, hepatitis B, hepatitis C, or HIV infection.\n* Individuals with history of more than one episode of herpes zoster and/or opportunistic infections in the last 12 months, with the exception of non-invasive herpes simplex at any site, oral candidiasis, vaginal candidiasis, or cutaneous fungal infections, which are permitted within the prior 12 months unless of unusual severity. Individuals with a prior history of ophthalmic herpes zoster will be excluded.\n* Active infections requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring intravenous (IV) antibiotics within 12 months prior to screening.\n* Last administration of experimental biologic or oral agents \\< 6 months or 5 half-lives, whichever is longer, before screening.\n* Individuals who have had previous treatment with any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, inebilizumab, or ofatumumab) within 12 months or other B cell targeting therapy (eg, belimumab) or anti-type I IFN pathway therapy (eg, anifrolumab) \\< 6 months before randomization.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amgen Call Center",
                    "role": "CONTACT",
                    "phone": "866-572-6436",
                    "email": "medinfo@amgen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MD",
                    "affiliation": "Amgen",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Neurovations",
                    "status": "RECRUITING",
                    "city": "Napa",
                    "state": "California",
                    "zip": "94558-2415",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.29714,
                        "lon": -122.28553
                    }
                },
                {
                    "facility": "Clinical Research of West Florida Inc - Tampa",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33606-1246",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Tekton Research, LLC - W Gate Blvd - Austin - PPDS",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78745",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "R & H Clinical Research-777 S Fry Rd",
                    "status": "RECRUITING",
                    "city": "Katy",
                    "state": "Texas",
                    "zip": "77450-2297",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.78579,
                        "lon": -95.8244
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "AmgenTrials clinical trials website",
                    "url": "http://www.amgentrials.com"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.",
            "accessCriteria": "Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.",
            "url": "http://www.amgen.com/datasharing"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012859",
                    "term": "Sjogren's Syndrome"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000001172",
                    "term": "Arthritis, Rheumatoid"
                },
                {
                    "id": "D000001168",
                    "term": "Arthritis"
                },
                {
                    "id": "D000007592",
                    "term": "Joint Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000012216",
                    "term": "Rheumatic Diseases"
                },
                {
                    "id": "D000014987",
                    "term": "Xerostomia"
                },
                {
                    "id": "D000012466",
                    "term": "Salivary Gland Diseases"
                },
                {
                    "id": "D000009059",
                    "term": "Mouth Diseases"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                },
                {
                    "id": "D000015352",
                    "term": "Dry Eye Syndromes"
                },
                {
                    "id": "D000007766",
                    "term": "Lacrimal Apparatus Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15664",
                    "name": "Sjogren's Syndrome",
                    "asFound": "Sjogren's Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18040",
                    "name": "Dry Eye Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10664",
                    "name": "Keratoconjunctivitis Sicca",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4476",
                    "name": "Arthritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4480",
                    "name": "Arthritis, Rheumatoid",
                    "relevance": "LOW"
                },
                {
                    "id": "M10621",
                    "name": "Joint Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15045",
                    "name": "Rheumatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6323",
                    "name": "Collagen Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17724",
                    "name": "Xerostomia",
                    "relevance": "LOW"
                },
                {
                    "id": "M15285",
                    "name": "Salivary Gland Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12019",
                    "name": "Mouth Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10786",
                    "name": "Lacrimal Apparatus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        }
    },
    "hasResults": false
}